More on the CRISPR patent matter
IPBiz has been covering the patent issues with CRISPR (e.g.,
Will there be an interference between the Zhang and Doudna work on CRISPR? ;
CRISPR is high profile in science, patents; competitor labeled a mere second comer )
Further to IPBiz posts on the CRISPR matter, note
UPDATE on 22 July 2015
Note the text: On the other hand, a third party has filed documentation in support of a claim against the Doudna application for failure to comply with the duty of candor and good faith, which encompasses the duty to disclose prior art; thus, invalidating any patent that might issue from the Doudna application.
A finding of inequitable conduct renders the claims of the associated patent unenforceable, not invalid.